{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:10:08Z","timestamp":1790266208800,"version":"4.1.0"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n The Breast Cancer Index (BCI) is an established genomic assay that provides individualized risks of overall and late distant recurrence and predicts the likelihood of extended endocrine therapy (EET) benefit in patients with early-stage, hormone receptor\u2013positive (HR+) breast cancer. Previous findings from the first 1000 patients in the prospective BCI Registry showed that physicians changed their EET recommendation in more than 40% of patients.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate the use of the BCI in the full registry cohort and how physicians integrate prognostic and predictive results in real care settings.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n The BCI Registry study is a US multicenter evaluation of long-term clinical outcome, decision impact, and medication adherence among patients enrolled from April 2021 to January 2024. Participants included women diagnosed with early-stage, HR+ breast cancer. Physician and patient questionnaires about recommendations or preferences for EET and confidence or comfort with these decisions were collected. For this cohort study, data were analyzed from January 2025 to March 2026.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n \n Patients received BCI testing and endocrine therapy. The BCI prognostic model calculated a risk score to classify patients as having low or high risk of late distant recurrence, while the BCI predictive component used the BCI\n HOXB13\/IL17BR<\/jats:italic>\n (H\/I) ratio to classify patients as having low or high likelihood of EET benefit.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Change in physicians\u2019 and patients\u2019 recommendations or preferences for EET, and their confidence or comfort with these decisions. Pre-BCI and post-BCI results were analyzed using the McNemar test. Fisher exact test was used to determine the association between BCI categories and clinical variables.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The final analysis included 2900 women with completed physician and patient questionnaires (mean [SD] age, 65.2 [10.3] years). Among these patients, 2570 (88.6%) were postmenopausal, 2245 (77.4%) were N0, and 2501 (86.2%) were HER2-negative. After BCI testing, 1209 physicians (41.7%) changed their EET recommendation (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), and 1479 patients (51.0%) changed their preference for EET (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Among 1100 patients classified as BCI (H\/I)\u2013High, EET recommendations increased from 671 pre-BCI (61.0%) to 1014 post-BCI (92.2%). Among 1800 patients classified as BCI (H\/I)\u2013Low, the number of physicians not recommending EET increased from 856 (47.6%) to 1576 (87.6%). Physician confidence in their recommendation increased for 1269 patients (43.8%;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), and 1260 patients (43.4%) were more comfortable with the EET decision (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This cohort study of patients from the BCI Registry highlights the important treatment guidance provided by the BCI to reduce EET undertreatment or overtreatment and further substantiates its clinical utility to individualize patient care.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.34974","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:32:35Z","timestamp":1790263955000},"page":"e2634974","source":"Crossref","is-referenced-by-count":0,"title":["Breast Cancer Index and Recommendations for Extended Endocrine Therapy"],"prefix":"10.1001","volume":"9","author":[{"given":"Tara B.","family":"Sanft","sequence":"first","affiliation":[{"name":"Hartford Healthcare Cancer Institute, Fairfield, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Siuliukina","sequence":"additional","affiliation":[{"name":"Biotheranostics, A Hologic Company, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"O\u2019Neal","sequence":"additional","affiliation":[{"name":"Biotheranostics, A Hologic Company, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar","family":"Khojandi","sequence":"additional","affiliation":[{"name":"Biotheranostics, A Hologic Company, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel C.","family":"Jankowitz","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Abrahamson Cancer Center, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Pegram","sequence":"additional","affiliation":[{"name":"Stanford Comprehensive Cancer Institute, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Diab","sequence":"additional","affiliation":[{"name":"Common Spirit, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Biotheranostics, A Hologic Company, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda K.L.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Biotheranostics, A Hologic Company, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Treuner","sequence":"additional","affiliation":[{"name":"Biotheranostics, A Hologic Company, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce A.","family":"O\u2019Shaughnessy","sequence":"additional","affiliation":[{"name":"Baylor University Medical Center, Texas Oncology, Sarah Cannon Research Institute, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"27","key":"zoi260945r1","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1200\/JCO.2009.25.9655","article-title":"Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.","volume":"28","author":"Hershman","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10503","key":"zoi260945r2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0140-6736(25)01013-X","article-title":"Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.","volume":"406","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2025","journal-title":"Lancet"},{"issue":"9793","key":"zoi260945r3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"issue":"26","key":"zoi260945r4","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1056\/NEJMra1307118","article-title":"Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer.","volume":"383","author":"Burstein","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"zoi260945r6","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1200\/JCO.22.00069","article-title":"Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update.","volume":"40","author":"Andre","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"zoi260945r7","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1158\/1078-0432.CCR-24-3836","article-title":"Identification of early-stage breast cancer with a minimal risk of recurrence by the Breast Cancer Index.","volume":"31","author":"Jilderda","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"1","key":"zoi260945r8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41523-025-00885-x","article-title":"Validation of minimal risk of recurrence classification by the Breast Cancer Index in early stage breast cancer.","volume":"12","author":"Jilderda","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"zoi260945r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2026.104714","article-title":"Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer index.","volume":"86","author":"O\u2019Regan","year":"2026","journal-title":"Breast"},{"issue":"11","key":"zoi260945r10","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/annonc\/mdz289","article-title":"Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.","volume":"30","author":"Bartlett","year":"2019","journal-title":"Ann Oncol"},{"issue":"9","key":"zoi260945r11","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1158\/1078-0432.CCR-21-3385","article-title":"Breast Cancer Index is a predictive biomarker of treatment benefit and outcome from extended tamoxifen therapy: final analysis of the Trans-aTTom study.","volume":"28","author":"Bartlett","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"zoi260945r12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/1078-0432.CCR-20-2737","article-title":"Breast Cancer Index predicts extended endocrine benefit to individualize selection of patients with HR(+) early-stage breast cancer for 10 years of endocrine therapy.","volume":"27","author":"Noordhoek","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"14","key":"zoi260945r13","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/jnci\/djt146","article-title":"Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13\/IL17BR biomarker.","volume":"105","author":"Sgroi","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"zoi260945r14","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/S1470-2045(13)70387-5","article-title":"Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.","volume":"14","author":"Sgroi","year":"2013","journal-title":"Lancet Oncol"},{"issue":"15","key":"zoi260945r15","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1158\/1078-0432.CCR-13-0804","article-title":"Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence.","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"2","key":"zoi260945r16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.6004\/jnccn.2023.7087","article-title":"Impact of the Breast Cancer Index for extended endocrine decision-making: first results of the Prospective BCI Registry Study.","volume":"22","author":"Sanft","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"zoi260945r17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.40931","article-title":"Assessment of ovarian function suppression (OFS)-containing adjuvant endocrine therapy in premenopausal women by Breast Cancer Index.","volume":"8","author":"O\u2019Regan","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"23","key":"zoi260945r18","doi-asserted-by":"publisher","first-page":"7217","DOI":"10.1158\/1078-0432.CCR-17-1688","article-title":"A novel Breast Cancer Index for prediction of distant recurrence in HR(+) early-stage breast cancer with one to three positive nodes.","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"zoi260945r19","doi-asserted-by":"publisher","DOI":"10.2217\/bmt-2019-0001","article-title":"A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making.","volume":"8","author":"Sanft","year":"2019","journal-title":"Breast Cancer Manag"},{"issue":"3","key":"zoi260945r20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10549-015-3631-9","article-title":"Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.","volume":"154","author":"Sanft","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"zoi260945r5","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines). Breast cancer, version 1.2026. 2026. Accessed February 1, 2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?id=1419"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2854437\/sanft_2026_oi_260945_1789583144.98298.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:32:37Z","timestamp":1790263957000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2854437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.34974","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]}}}